Auris Initiates Second Phase III For Pipeline-Leading Hearing Loss Drug

 
• By Lucie Ellis-Taitt

Auris Medical Holding AG has moved its hearing loss therapeutic, AM-111, into a second Phase III study, making it the most advanced drug in the pipeline for the treatment of sudden deafness, according to Biomedtracker.

SC1606_Membranous-labyrinth_1200
Membranous labyrinth and vestibulocochlear nerve • Source: Copyright of Primal Pictures, an Informa business 2016. For more information please go to www.primalpictures.com

More from Clinical Trials

More from R&D